Quest Diagnostics is charging full speed ahead with its previously announced joint venture with global CRO Quintiles, launching the companies' new business, dubbed Q2 Solutions, to provide lab services for clinical trials and to expand its diagnostics footprint.
Quintiles and Quest Diagnostics rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests.
GVK BioSciences, an Indian CRO under fire from European regulators, has signed a deal with Australia's Akaal Pharma to help the company move its in-development psoriasis treatment into mid-stage trials.
Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.
The government of Equatorial Guinea has teamed up with Marathon Oil, Noble Energy and AMPCO to sponsor the development of the Sanaria PfSPZ vaccine against malaria. The $48.5 million in funding includes support for clinical trials from 2015 to 2018, Sanaria said in a statement.
The API of GlaxoSmithKline's HIV therapy Tivicay (dolutegravir) will be made in China by Shanghai-based Desano Pharmaceuticals under a deal with the British drug maker's ViiV Healthcare arm, according to a press release.
Electronic medical records company Allscripts took a $200 million (or 10%) stake in drug discovery company NantHealth to strengthen their alliance focused on personalized medicine in the cancer treatment arena.
Qiagen relies on companion diagnostics to keep its engine running, and the company is looking to gain some ground in the field through a new joint venture with German molecular diagnostics outfit Biotype Diagnostic.
Celgene is paying about $1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $150 million upfront and paying $93 a share--a huge premium--to snap up 9.1 million shares of Juno Therapeutics, inking a collaboration to develop and commercialize new oncology therapies.
Australia's CSL unveiled Phase III trial results for hemophilia B candidate rIX-FP that met the primary endpoint and separately noted it bought exclusive rights to commercialize flu treatment Rapivab from BioCryst Pharmaceuticals last week. The note highlighted the growing reach of the biopharma in a core blood products business and in vaccines following its purchase of a Novartis unit last year.